In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback